ZielBio raises $25M series A to advance two new cancer targets

ZielBio raised a $25 million series A round from Morningside and Partners Innovation Fund to advance a functional proteomics platform that has generated two first-in-class preclinical mAbs targeting CSP1 and HRNR.

The company was founded in 2010 by University of Virginia professor Kimberly Kelly with about $800,000 in seed funding from angel investors. It is now using the series A funding to bring its lead program against CSP1 into the clinic and build out its pipeline by validating new targets. ...